Interestingly, treatment with recombinant MESD protein, a LRP5/6 chaperone protein able to bind to mature LRP5 and LRP6 on the cell surface, decreases LRP6 phosphorylation in prostate cancer cells, inhibiting their proliferation and tumorigenic potential (Table 2) [123,124]. This evidence concerns the gene LRP6 and prostate cancer.